350 related articles for article (PubMed ID: 35489270)
41. Synthesis, in vitro anticancer and antibacterial activities and in silico studies of new 4-substituted 1,2,3-triazole-coumarin hybrids.
Kraljević TG; Harej A; Sedić M; Pavelić SK; Stepanić V; Drenjančević D; Talapko J; Raić-Malić S
Eur J Med Chem; 2016 Nov; 124():794-808. PubMed ID: 27639370
[TBL] [Abstract][Full Text] [Related]
42. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA
Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
[TBL] [Abstract][Full Text] [Related]
44. Exploration of antiproliferative potential of modified triazole-benzohydrazone scaffold: Multitarget approach.
Ali AM; Khalaf MA; Bhongade BA; Selim KB; Mostafa AS
Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300383. PubMed ID: 37946599
[TBL] [Abstract][Full Text] [Related]
45. Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors:
Taghour MS; Elkady H; Eldehna WM; El-Deeb NM; Kenawy AM; Elkaeed EB; Alsfouk AA; Alesawy MS; Metwaly AM; Eissa IH
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1903-1917. PubMed ID: 35801403
[TBL] [Abstract][Full Text] [Related]
46. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
47. Exploration of novel VEGFR2 tyrosine kinase inhibitors via design and synthesis of new alkylated indolyl-triazole Schiff bases for targeting breast cancer.
Nafie MS; Boraei ATA
Bioorg Chem; 2022 May; 122():105708. PubMed ID: 35290929
[TBL] [Abstract][Full Text] [Related]
48. Design and synthesis of new 2-oxoquinoxalinyl-1,2,4-triazoles as antitumor VEGFR-2 inhibitors.
Zengin M; Unsal Tan O; Arafa RK; Balkan A
Bioorg Chem; 2022 Apr; 121():105696. PubMed ID: 35217379
[TBL] [Abstract][Full Text] [Related]
49. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000219. PubMed ID: 33197080
[TBL] [Abstract][Full Text] [Related]
50. Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity.
Mahmoud HK; Farghaly TA; Abdulwahab HG; Al-Qurashi NT; Shaaban MR
Eur J Med Chem; 2020 Dec; 208():112752. PubMed ID: 32947227
[TBL] [Abstract][Full Text] [Related]
51. Hybrids of thiazolidinone with 1,2,3-triazole derivatives: design, synthesis, biological evaluation,
Bimoussa A; Fawzi M; Oubella A; Ejaz SA; Sajjad Bilal M; Labd Taha M; Auhmani A; Morjani H; Robert A; Riahi A; Ait Itto MY
J Biomol Struct Dyn; 2023; 41(21):11987-11999. PubMed ID: 36617941
[TBL] [Abstract][Full Text] [Related]
52. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
El-Adl K; El-Helby AA; Sakr H; Elwan A
Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
[TBL] [Abstract][Full Text] [Related]
53. Synthesis of novel nicotinic acid derivatives of potential antioxidant and anticancer activity.
El-Dash Y; Khalil NA; Ahmed EM; Hassanin SO; Gowifel AMH; Hassan MSA
Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300250. PubMed ID: 37792247
[TBL] [Abstract][Full Text] [Related]
54. Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases.
Elzahhar PA; Abd El Wahab SM; Elagawany M; Daabees H; Belal ASF; El-Yazbi AF; Eid AH; Alaaeddine R; Hegazy RR; Allam RM; Helmy MW; Bahaa Elgendy ; Angeli A; El-Hawash SA; Supuran CT
Eur J Med Chem; 2020 Aug; 200():112439. PubMed ID: 32485532
[TBL] [Abstract][Full Text] [Related]
55. Discovery of pyridine- sulfonamide hybrids as a new scaffold for the development of potential VEGFR-2 inhibitors and apoptosis inducers.
Ahmed MF; Santali EY
Bioorg Chem; 2021 Jun; 111():104842. PubMed ID: 33798847
[TBL] [Abstract][Full Text] [Related]
56. Novel 3-phenylquinazolin-2,4(1H,3H)-diones as dual VEGFR-2/c-Met-TK inhibitors: design, synthesis, and biological evaluation.
Hassan A; Mosallam AM; Ibrahim AOA; Badr M; Abdelmonsef AH
Sci Rep; 2023 Oct; 13(1):18567. PubMed ID: 37903949
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and Preclinical Evaluation of Indole Triazole Conjugates as Microtubule Targeting Agents that are Effective against MCF-7 Breast Cancer Cell Lines.
Yele V; Pindiprolu SKSS; Sana S; Ramamurty DSVNM; Madasi JRK; Vadlamani S
Anticancer Agents Med Chem; 2021; 21(8):1047-1055. PubMed ID: 32981511
[TBL] [Abstract][Full Text] [Related]
58. Design, synthesis, and apoptotic antiproliferative action of new 1,2,3-triazole/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors.
Mahmoud MA; Mohammed AF; Salem OIA; Almutairi TM; Bräse S; Youssif BGM
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2305856. PubMed ID: 38326989
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and Characterization of a New Class of Chromene-Azo Sulfonamide Hybrids as Promising Anticancer Candidates with the Exploration of Their EGFR,
Alblewi FF; Alsehli MH; Hritani ZM; Eskandrani A; Alsaedi WH; Alawad MO; Elhenawy AA; Ahmed HY; El-Gaby MSA; Afifi TH; Okasha RM
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069037
[TBL] [Abstract][Full Text] [Related]
60. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma.
Eissa IH; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; Abdelhady AA; Elhendawy MA; Radwan MM; ElSohly MA; Mahdy HA
Bioorg Chem; 2021 Feb; 107():104532. PubMed ID: 33334586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
